Follow The Filings

DSGN Design Therapeutics

Design Therapeutics earnings company data as of 4:45 AM ET 11/1

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 4 Nov EPS -0.35 — —
Rev — — —

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
SCHEDULE 13G —
SCHEDULE 13G/A —
8-K 2.02,9.01
10-Q
8-K 5.07
SCHEDULE 13G —
8-K 8.01
SCHEDULE 13G/A —
8-K 2.02,7.01
10-Q
DEF 14A
DEFA14A
8-K 5.02
SCHEDULE 13D/A —
8-K 2.02,9.01
10-K
SCHEDULE 13G/A —
8-K 5.02
SCHEDULE 13D/A —
SCHEDULE 13D/A —
8-K 2.02,9.01
10-Q
8-K 5.02
SCHEDULE 13G —
10-Q

Insider forms

Forms 3, 4 and 5 from EDGAR, 1 row shown

Filed Form Detail Links
4 Period Jun 9, 2026 (5 forms)

10 more insider forms

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.